Sarah M. Trinder

Sarah M. Trinder

Auto-generated profile, based on publicly available information

Sarah M. Trinder

Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation Perth Children's Hospital Perth Western Australia Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2025 in Targeted Oncology
Verified
Journal Article
Open access
PDF file
STSarah M. Trinder
Sarah M. Trinder
DZDavid Ziegler
David Ziegler
LLLoretta Lau
Loretta Lau
The advent of comprehensive genomic sequencing has catalysed the emergence of paediatric precision medicine platforms globally. These have established the feasibility of profiling tumours at scale, enhancing our understanding of the genetic landscape of paediatric tumours and enabling identification of driver mutations and actionable targets. In turn, this has created the opportunity for development of novel precision-guided therapies (PGT). This commentary synthesizes evidence from major collaborative trials with a focus on outcome reporting, particularly in the relapsed/refractory and high-risk patient cohorts. Patients receiving PGT in these cohorts demonstrate meaningful responses and survival benefit, particularly when treatment is based on high-level clinical evidence and administered early in the disease course. However, challenges remain in addressing low uptake of PGT, likely hindered by substantial barriers in access and complex pharmaceutical regulatory constraints. Furthermore, heterogeneity in recommendation and outcome reporting hinders data harmonisation and generalisability of results. In addition to improving outcomes, comprehensive profiling can contribute to diagnostic refinement and identification of germline variant detection in a subset of patients. Emerging studies, conducted through national initiatives, signify the potential benefit of precision medicine for all patients with childhood cancer regardless of risk. A dynamic approach to address challenges and ensure cost–benefit is necessary to embed precision oncology as a standard of care for all children with cancer.

27 December 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
STSarah M Trinder
Sarah M Trinder
JSJohnathan Soggee
Johnathan Soggee
JSJessica Spragg
Jessica Spragg
DADaniel Alexander
Daniel Alexander
RMRichard Mitchell
Richard Mitchell
SRShanti Ramachandran
Shanti Ramachandran

3 March 2025 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
STS. M. Trinder
S. M. Trinder
CKC. Kiraly‐Borri
C. Kiraly‐Borri
HDH. Dholaria
H. Dholaria
ACA. Charles
A. Charles
DRD. J. Roebuck
D. J. Roebuck
ARA. L. Ryan
A. L. Ryan

30 January 2026 in Neuro-Oncology Pediatrics
Verified
Journal Article
Open access
STSarah M Trinder
Sarah M Trinder
NGNicholas G Gottardo
Nicholas G Gottardo
RKRishi S Kotecha
Rishi S Kotecha
Metastatic meningioma in childhood and adolescence is an extremely rare entity, with limited available data. We sought to characterize features, treatment and outcomes by performing a systematic review of all cases of metastatic meningioma diagnosed before 18 years of age published since 1989. We found metastases predominantly occurred in patients with grade 2 and 3 tumors and in the context of local relapse. Most metastatic sites were extracranial, with lung/pleura the dominant extracranial site. The remainder occurred at distant sites within the central nervous system. We propose that screening of these sites should be considered if relapse is suspected.

10 August 2026 in Journal of Paediatrics and Child Health
Verified
Journal Article
Open access
PDF file
MOMatthew J. O'COnnor
Matthew J. O'COnnor
MMMichelle Martin
Michelle Martin
STSarah M. Trinder
Sarah M. Trinder
DBDraga Barbaric
Draga Barbaric
DHDiane Hanna
Diane Hanna
SCSiobhan Cross
Siobhan Cross
Background: Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. Methods: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. Results: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. Conclusions: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.